Stock Market logoStock Market Station

All the stock market news, every minute updated!

20 June 2021
14:13 hour

Sanofi, GSK's mid-stage COVID-19 vaccine trial shows strong immune responses in adults

Seeking Alpha

17/05/2021 - 08:54


READ THE FULL ARTICLE ON SEEKING ALPHA

Related headlines:

  1. GSK, Medicago's COVID-19 vaccine induces "robust" immune responses in adults (18/05/2021 - Seeking Alpha)

    [visit article]
  2. Sanofi, GSK to launch new mid-stage 2 study of COVID-19 vaccine candidate (22/02/2021 - Seeking Alpha)

    [visit article]
  3. Coronavirus Update: CureVac’s vaccine disappoints in major trial, says it was poor match against 29 COVID variants (17/06/2021 - Market Watch)
    The global tally of confirmed cases of COVID-19 climbed above 177 million on Thursday, a day after disappointing news from CureVac with the German company saying its vaccine was only 47% effective in a late-stage clinical trial.
    [visit article]
  4. : A plant-based vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response (18/05/2021 - Market Watch)
    Trial participants have 10 times more antibodies in their systems than patients recovering from COVID-19.
    [visit article]
  5. : French vaccine maker Valneva launches Phase 3 trial of its COVID-19 shot after snubbing EU (22/04/2021 - Market Watch)
    Study will compare how immune systems respond to Valneva’s vaccine candidate with the one jointly developed by AstraZeneca and the University of Oxford.
    [visit article]
  6. Vaccine for All: Credit war rages after Centre opens Covid-19 vaccine for all adults (20/04/2021 - Financial Express)
    Opposition leaders made a beeline, taking to social media platforms soon after the announcement to suggest that they were the first among all to demand that the government allow vaccines for all adults.
    [visit article]
  7. The Conversation: What does a strong reaction to a COVID-19 vaccine mean? (19/04/2021 - Market Watch)
    A doctor explains whether experiencing side effects from the Pfizer, Moderna or J&J vaccine signals how well your immune system is working.
    [visit article]
  8. Clover Bio's COVID-19 vaccine candidate shows immune response against SARS-CoV-2 variants in mouse model (18/05/2021 - Seeking Alpha)

    [visit article]
  9. Regeneron and Sanofi updates data from late-stage trial for Libtayo in cervical cancer (12/05/2021 - Seeking Alpha)

    [visit article]
  10. Regeneron, Sanofi post promising data from late-stage Dupixent asthma trial (17/05/2021 - Seeking Alpha)

    [visit article]
  11. Capitol Report: Biden aims for 70% of U.S. adults getting at least 1 vaccine dose by July 4 (04/05/2021 - Market Watch)
    President Joe Biden on Tuesday announces a new goal of getting 70% of U.S. adults vaccinated with at least one COVID-19 vaccine dose by the Fourth of July, along with having 160 million adults fully vaccinated by that holiday.
    [visit article]
  12. Sinovac says its vaccine is safe for children as young as 3 (23/03/2021 - Financial Express)
    More than 70 million shots of Sinovac's vaccine have been given worldwide, including in China. China has approved its use in adults but it has not yet been used in children, because their immune systems may respond differently to the vaccine.
    [visit article]
  13. : Young, healthy adults will be deliberately reinfected with COVID-19 to boost vaccine development (19/04/2021 - Market Watch)
    Researchers at the University of Oxford have launched a "human challenge" trial to investigate what happens when someone who has recovered from COVID-19 is re-exposed to the virus
    [visit article]
  14. No mix and match of Covid-19 vaccine doses anytime soon: VK Paul, member-health, Niti Aayog (23/05/2021 - Financial Express)
    Preliminary results from a trial in UK, where a combination of the Oxford-AstraZeneca and Pfizer-BioNTech Covid-19 vaccines were given, generated high immune response against the SARS-COV-2 virus.
    [visit article]
  15. Altimmune gains 7% after AdCOVID shows strong immune response against COVID-19 variant in preclinical study (26/05/2021 - Seeking Alpha)

    [visit article]
  16. AbCellera-discovered bamlanivimab combo shows promise in late-stage COVID-19 trial (10/03/2021 - Seeking Alpha)

    [visit article]
  17. Valneva initiates pivotal late-stage COVID-19 vaccine trial (21/04/2021 - Seeking Alpha)

    [visit article]
  18. GSK/ Medicago begin late-stage trial for plant-derived COVID-19 vaccine (16/03/2021 - Seeking Alpha)

    [visit article]
  19. Valneva completes recruitment for late-stage inactivated COVID-19 vaccine trial (03/06/2021 - Seeking Alpha)

    [visit article]
  20. Moderna initiates early-stage trial for refrigerator stable COVID-19 vaccine (15/03/2021 - Seeking Alpha)

    [visit article]
  21. Sanofi's amcenestrant combo shows encouraging antitumor activity in early-stage breast cancer study (20/05/2021 - Seeking Alpha)

    [visit article]
  22. AC Immune expands Phase 1b/2a phospho-Tau Alzheimer’s vaccine trial (17/05/2021 - Seeking Alpha)

    [visit article]
  23. : AstraZeneca’s new COVID-19 vaccine trial data will give the shot a U.S. boost (22/03/2021 - Market Watch)
    The COVID-19 vaccine of the U.K.-Swedish pharmaceuticals group AstraZeneca has shown robust results in its U.S. trial, the company said on Monday.
    [visit article]
  24. : CureVac stock drops more than 50% on news trial COVID vaccine 47% effective (16/06/2021 - Market Watch)
    Shares of Curevac NV tanked more than 50% in the extended session Wednesday after the pharma company said its trial COVID-19 vaccine showed an efficacy of 47% against the illness.
    [visit article]
  25. Immunic’s oral immune therapy shows positive effect rare liver disease trial (18/02/2021 - Seeking Alpha)

    [visit article]
  26. Trial for second SII Covid vaccine begins in Pune (26/03/2021 - Financial Express)
    ICMR has partnered with SII to conduct phase 2/3 bridging clinical trials of the vaccine. The trial is being led by ICMR - National AIDS Research Institute in Pune. The SARS-CoV-2 recombinant spike protein nanoparticle vaccine has reported efficacy of 96.4%.
    [visit article]
  27. : CVS banks on future gains from pediatric vaccines as hesitant adults drive recent COVID vaccination decline (04/05/2021 - Market Watch)
    CVS Health Corp. said it has recently seen a decline in the number of adults coming in for COVID-19 vaccine shots, but its outlook for the rest of the year assumes gains from the administration of pediatric vaccines.
    [visit article]
  28. Moderna inks COVID-19 vaccine manufacturing deal with Sanofi (26/04/2021 - Seeking Alpha)

    [visit article]
  29. Sanofi, GSK initiate Phase 3 study of COVID-19 vaccine candidate (27/05/2021 - Seeking Alpha)

    [visit article]
  30. Sanofi's mRNA COVID-19 vaccine candidate not ready this year, CEO says (14/02/2021 - Investing.com)

    [visit article]
  31. Huge Potential: MOON is just a stop with those!!!! (14/02/2021 - Reddit Stocks)
    Hi guys, below you can find my view for some value plays/hidden ???? from bio sector;) These companies are often targeted by short vultures too! This is not a financial advise as I am just a guy like you;) Please note that I have positions for the below and I am holding with my diamond hands. ATOS, Atossa Therapeutics has 2 candidates targeting COVID (Nasal Spray looks very promising) and 1 candidate targeting breast cancer for which recently reported great trial results. ATOS has the potential to explode from the current levels especially with a short squeeze as the vultures are always around, market cap is still low and number of outstanding shares is not high! It is well funded at the moment as some offerings took place and new ones are not expected. Fair value should be around 15$ and sky is the limit especially if breast cancer treatment will deliver good results. Buyout from big pharma can be also a case as only breast cancer is a multi billion $$$ market. ADTX, ADiTx Therapeutics has an innovative program called AditxtScore and also AditxtReprogramming in their pipeline. AditxtScore monitors the individual’s immune system as an example can work with COVID for detection and with vaccines to monitor the antibodies so 2in1 and there are more applications like drug administration etc. AditxtReprogramming is focused on organ transplantation and the immune responses. This is another short target, low market cap and small amount of shares waiting to explode! Price expectation is also around $15 and sky is the limit! Buyout target too. Last but not least NVAX, Novavax with the best in class COVID vaccine and upcoming EUA/more deals should be around 600-1000$ if we compare the current market cap with Moderna’s. Has Nanoflu (seasonal flu vaccine) and will submit to FDA for approval as trials were successful, RSV vaccine in the pipeline along with combo of COVID/Nanoflu! Let’s reward companies trying to save lives and help people in need! I like the juice from squeezed shorts btw!!!! Bonus hint to do some research: google RLF-100 XRays, I like Swiss cheese and chocolate ;)) Good luck to all and stay safe!   submitted by   /u/AllSeeingEye7 [link]   [comments]
    [visit article]
  32. Sanofi remains hopeful in ‘finding a place’ in COVID-19 vaccine race (29/04/2021 - Seeking Alpha)

    [visit article]
  33. Sanofi, Translate Bio (TBIO) on go with study of mRNA COVID-19 vaccine candidate (12/03/2021 - Seeking Alpha)

    [visit article]
  34. Sanofi remains hopeful in ‘finding a place’ in COVID-19 vaccine race (29/04/2021 - Seeking Alpha)

    [visit article]
  35. : Fauci insists that AstraZeneca’s COVID-19 vaccine candidate is ‘good’ after issue with information in company’s press release (24/03/2021 - Market Watch)
    Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, again sought to reassure Americans that AstraZeneca’s still-experimental COVID-19 vaccine is a strong candidate even though the drug maker reportedly miscommunicated findings from a clinical trial earlier this week.
    [visit article]
  36. : Fauci insists that AstraZeneca’s COVID-19 vaccine candidate is ‘good’ after issue with information in company’s press release (24/03/2021 - Market Watch)
    Dr. Anthony Fauci, President Joe Biden’s chief medical advisor, again sought to reassure Americans that AstraZeneca’s still-experimental COVID-19 vaccine is a strong candidate even though the drug maker reportedly miscommunicated findings from a clinical trial earlier this week.
    [visit article]
  37. SpringWorks’ mid-stage neurofibromatosis trial shows 50% objective response rate (25/02/2021 - Seeking Alpha)

    [visit article]
  38. Annovis' Parkinson's disease treatment ANVS401 shows promise in mid-stage trial (19/05/2021 - Seeking Alpha)

    [visit article]
  39. Astellas’ non hormonal therapy shows positive effect on hot flashes in late-stage trial (19/02/2021 - Seeking Alpha)

    [visit article]
  40. AstraZeneca shows clinical benefit of Lynparza in late-stage trial for breast cancer (03/06/2021 - Seeking Alpha)

    [visit article]
  41. Acceleron's sotatercept shows potential to treat pulmonary arterial hypertension in mid-stage Pulsar trial (19/05/2021 - Seeking Alpha)

    [visit article]
  42. AstraZeneca COVID-19 vaccine is now offered to all adults in Germany (06/05/2021 - Seeking Alpha)

    [visit article]
  43. Two Pfizer vaccine doses provide over 95% protection against COVID-19, says analysis in Israel (06/05/2021 - Financial Express)
    A single dose of this covid vaccine was associated with 58 per cent protection against infection, 76 per cent protection against hospitalization, and 77 per cent against death, emphasizing the importance of vaccinating adults fully.
    [visit article]
  44. : World’s first COVID-19 ‘booster trial’ will give third vaccine dose to U.K. volunteers (20/05/2021 - Market Watch)
    Thousands of volunteers will be given a third dose of COVID-19 vaccines as part of a clinical trial to examine whether a “booster” shot can protect against COVID-19 and new coronavirus disease variants.
    [visit article]
  45. : Young healthy adults will be paid £4,500 to be deliberately infected with COVID-19 in new trial (17/02/2021 - Market Watch)
    A COVID-19 trial that will see healthy young people paid £4,500 to be deliberately infected with coronavirus has been given ethics approval in the U.K.
    [visit article]
  46. : Young healthy adults will be paid £4,500 to be deliberately infected with COVID-19 in new trial (17/02/2021 - Market Watch)
    A COVID-19 trial that will see healthy young people paid £4,500 to be deliberately infected with coronavirus has been given ethics approval in the U.K.
    [visit article]
  47. : Moderna and Novavax added to ‘mix and match’ COVID-19 vaccine trial (14/04/2021 - Market Watch)
    A major U.K. trial looking at whether COVID-19 vaccines can be safely mixed has been expanded to include shots made by Moderna and Novavax, researchers announced on Wednesday.
    [visit article]
  48. : Mixing Pfizer and AstraZeneca COVID-19 vaccines increases mild side effects but is safe, study shows (13/05/2021 - Market Watch)
    Mixing doses of COVID-19 vaccines increases the risk of mild to moderate side effects when compared with administering two shots of the same vaccine, according to a U.K. trial.
    [visit article]
  49. Coronavirus: Oxford University to test Covid-19 vaccine response among children for first time (13/02/2021 - Financial Express)
    The University of Oxford has launched a study to assess the safety and immune response of the COVID-19 vaccine it has developed with AstraZeneca Plc in children for the first time, it said on Saturday.
    [visit article]

For more information mailto [email protected]. Disclaimer.